The pharmaceutical industry’s division devoted to the development, manufacturing, and distribution of drugs used to treat HIV (Human Immunodeficiency Virus) infection is known as the HIV Antivirals Market. The main method for treating HIV is called antiretroviral therapy (ART), and it uses a variety of antiviral medications to prevent the virus from replicating and decrease the disease’s progression.
By 2022, it is anticipated that the market for HIV antivirals will be worth US$ 30.6 billion. The market for HIV antivirals is anticipated to reach US$ 47.0 billion by the end of 2032, with a 4.4% CAGR in sales revenue between 2022 and 2032. According to a recent prediction, fixed-dose combinations (FDCs) would hold more than 83% of the market for HIV antivirals in 2021.
The increasing prevalence of HIV around the world is what is driving the demand for HIV antivirals. By 2020, the number of HIV-positive people worldwide is expected to reach roughly 37.7 million, according to UNAIDS, the Joint United Nations Programme on HIV/AIDS.
Download Our Sample Report Now and Embark on a Journey towards Innovation and Prosperity @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15095
The need for HIV antivirals will also rise as unprotected sex and the usage of tainted needles and syringes become more common. According to the 2019 National Youth Risk Behaviour Survey by the Centres for Disease Control and Prevention (CDC), 38% of respondents in the United States claimed having had sexual contact, while 9% said they had four or more partners.
Therefore, to capitalise on the rising demand for generic anti-HIV medications, major producers are doing so at a low cost. For example, cheaper generic versions of Lamivudine, Abacavir, and Efavirenz are available in the US than their branded equivalents. This is projected to generate a lucrative opportunity for producers of generic HIV antivirals to provide low- and middle-income people with access to affordable medical services.
Key Takeaways from Market Study:
- Because of their ability to increase adherence to an HIV treatment regimen, fixed-dose combinations (FDCs) owned more than 83.2% of the market value in 2021.
- Hospital pharmacies are the dominant sales channel for HIV antivirals, accounting for over 53.4% of the market in 2021, and are expected to increase at a CAGR of 4.5% over the next decade.
- In 2021, the United States dominated the North American HIV antivirals market, with a total market share of around 96.8%.
- Because of the increasing number of HIV patients in the country, India is likely to lead the growth in the South Asian market.
“With increasing awareness among the people about HIV causes and symptoms, the HIV antivirals market is set witness positive growth during the forecast period. Hence, key players are developing anti-HIC drugs vaccines to increase their revenue,” says an analyst of Future Market Insights.
Market Competition
Key Players:
- Merck & Co., Inc.
- Johnson & Johnson
- Genetech, Inc.
- Teva Pharmaceutical Industries Ltd.
- AbbVie
- Cipla
- Pfizer Inc.
- Mylan N.V.
Market players are expanding the business through collaborations, and increasing involvement in clinical trials as the key strategy with instances of key companies, such as Merck and Gilead, in order to improve their reach in the market and compete with other key players in forthcoming years. For instance:
- Merck reported positive results from two pivotal Phase 3 trials of the experimental, once-daily oral fixed-dose combination tablet of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection in October 2021.
- Gilead announced in March 2021, in collaboration with Merck, the development and marketing of long-acting, experimental therapy combinations of Lenacapavir and Islatravir in HIV.
Embrace Smarter Choices With Our Methodology-Derived Insights Today! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-15095
Key Market Segments Covered in HIV Antivirals Market Research
By Product:
- Fixed Dose Combinations (FDCs)
- Integrase Strand Transfer Inhibitors (INSTIs)
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Entry Inhibitors – CCR5 co-receptor antagonist
- Protease Inhibitors (PIs)
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
